Literature DB >> 34355179

Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.

Bhagyashri Rathod1, Shivam Chak1, Sagarkumar Patel1, Amit Shard1.   

Abstract

Pyruvate kinase M2 (PKM2) catalyzes the conversion of phosphoenolpyruvate (PEP) to pyruvate. It plays a central role in the metabolic reprogramming of cancer cells and is expressed in most human tumors. It is essential in indiscriminate proliferation, survival, and tackling apoptosis in cancer cells. This positions PKM2 as a hot target in cancer therapy. Despite its well-known structure and several reported modulators targeting PKM2 as activators or inhibitors, a comprehensive review focusing on such modulators is lacking. Herein we summarize modulators of PKM2, the assays used to detect their potential, the preferable tense (T) and relaxed (R) states in which the enzyme resides, lacunae in existing modulators, and several strategies that may lead to effective anticancer drug development targeting PKM2. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34355179      PMCID: PMC8292966          DOI: 10.1039/d1md00045d

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  143 in total

1.  Energy boost: the Warburg effect returns in a new theory of cancer.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

2.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  Allosteric mechanism of pyruvate kinase from Leishmania mexicana uses a rock and lock model.

Authors:  Hugh P Morgan; Iain W McNae; Matthew W Nowicki; Véronique Hannaert; Paul A M Michels; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  J Biol Chem       Date:  2010-02-01       Impact factor: 5.157

4.  The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site.

Authors:  Hugh P Morgan; Iain W McNae; Matthew W Nowicki; Wenhe Zhong; Paul A M Michels; Douglas S Auld; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

5.  Identification of small molecule inhibitors of pyruvate kinase M2.

Authors:  Matthew G Vander Heiden; Heather R Christofk; Eli Schuman; Alexander O Subtelny; Hadar Sharfi; Edward E Harlow; Jun Xian; Lewis C Cantley
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

6.  Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Authors:  Taro Hitosugi; Sumin Kang; Matthew G Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Z Chen; Jianxin Xie; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Titus J Boggon; Fadlo R Khuri; D Gary Gilliland; Lewis C Cantley; Jonathan Kaufman; Jing Chen
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

Review 7.  Activators of PKM2 in cancer metabolism.

Authors:  Steven L Warner; Kent J Carpenter; David J Bearss
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

8.  Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation.

Authors:  Jamie A Macpherson; Alina Theisen; Laura Masino; Louise Fets; Paul C Driscoll; Vesela Encheva; Ambrosius P Snijders; Stephen R Martin; Jens Kleinjung; Perdita E Barran; Franca Fraternali; Dimitrios Anastasiou
Journal:  Elife       Date:  2019-07-02       Impact factor: 8.713

9.  Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.

Authors:  Ke-Yan Cheng; Min Hao
Journal:  Med Sci Monit       Date:  2017-04-27

10.  Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells.

Authors:  Oliver A Stone; Mohamed El-Brolosy; Kerstin Wilhelm; Xiaojing Liu; Ana M Romão; Elisabetta Grillo; Jason K H Lai; Stefan Günther; Sylvia Jeratsch; Carsten Kuenne; I-Ching Lee; Thomas Braun; Massimo M Santoro; Jason W Locasale; Michael Potente; Didier Y R Stainier
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919

View more
  1 in total

1.  29th Annual GP2A Medicinal Chemistry Conference.

Authors:  Jean-Jacques Helesbeux; Laura Carro; Florence O McCarthy; Vânia M Moreira; Francesca Giuntini; Niamh O'Boyle; Susan E Matthews; Gülşah Bayraktar; Samuel Bertrand; Christophe Rochais; Pascal Marchand
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.